Christian Chabannon

Inserm — France

Medicine · Health Sciences

61h-index16.9kcitations591works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(281), CAR-T cell therapy research(115), Acute Myeloid Leukemia Research(104), Acute Lymphoblastic Leukemia research(72), Immune Cell Function and Interaction(58)

Publications590 total

Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link
Bone Marrow Transplantation·2025Open Access
The First France-Armenia Hematology Day: Medicine in the Service of Peace, Science and Bone Marrow Transplantation
Stem Cell Reviews and Reports·2025Open Access
Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee
HemaSphere·2025Open Access
Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation
Bone Marrow Transplantation·2025Open Access
Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium
Bone Marrow Transplantation·2025Open Access
Mapping the European landscape and specificity of ATMPs guidance
Cytotherapy·2025
Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium
Bone Marrow Transplantation·2025· 3 citedOpen Access
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplantation and Cellular Therapy·2025· 3 cited
CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party
Bone Marrow Transplantation·2025· 3 cited
Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
Current Research in Translational Medicine·2025· 1 citedOpen Access
Selecting patients with sickle cell disease for gene addition or gene editing‐based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference
HemaSphere·2025· 4 citedOpen Access
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party
Bone Marrow Transplantation·2025· 2 citedOpen Access
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT
Blood Reviews·2025· 3 citedOpen Access
Excellent Outcomes in Patients Receiving Tisagenlecleucel for R/R B-Cell ALL: Results from the European Post-Authorization Safety Study (PASS), on Behalf of the Ctiwp, PDWP and ALWP of the EBMT.
Transplantation and Cellular Therapy·2025· 1 cited
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium
Bone Marrow Transplantation·2025· 4 cited
Nurses’ reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT
Clinical Hematology International·2024· 1 citedOpen Access
Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
Blood·2024Open Access
The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party
Blood·2024Open Access
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
Bone Marrow Transplantation·2024· 1 cited
Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies
Best Practice & Research Clinical Haematology·2024· 9 citedOpen Access
page 1 of 30Next →

Frequent Co-authors

Mohamad Mohty(17), Ibrahim Yakoub‐Agha(13), John A. Snowden(12), Nicolaus Kröger(12), Didier Blaise(10), Grzegorz Basak(10), Rafael F. Duarte(10), Selim Corbacioglu(9), Arnon Nagler(9), Arjan C. Lankester(8), Chiara Bonini(8), Jürgen Kuball(8), Régis Peffault de Latour(7), Jan Styczyński(7), Anna Sureda(7), Catherine Faucher(7), Norbert Vey(6), Jakob Passweg(6), Helen Baldomero(6), Benjamin Esterni(6)